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Summary
BACKGROUND: Glomerulonephritis is a rare yet serious
group of diseases with a high risk of progression to end-
stage renal disease. For optimal healthcare planning, de-
tailed epidemiological and demographic data are essen-
tial. Despite their clinical relevance, these data are largely
lacking in Switzerland.
OBJECTIVE: The objective of this study was to assess the
incidence of the different forms of glomerulonephritis in the
western part of Switzerland and its changes over the last
10 years, compared with international data.
METHODS: We listed all renal biopsy reports analysed
between 2007 and 2016 at the University hospital of Lau-
sanne, the renal pathology reference centre of all hospitals
in the cantons of Vaud, Fribourg, Valais and Neuchâtel.
Biopsies with a first diagnosis of primary glomerulonephri-
tis were included in the analysis. The incidence was cal-
culated as the number of patients newly diagnosed with
glomerulonephritis divided by the number of inhabitants
of all the above-mentioned cantons during the year under
review, as retrieved from the federal statistical office of
Switzerland.
RESULTS: We collected biopsy reports from 864 patients
between 2007 and 2016; 168 biopsies met the inclusion
criteria. The most common primary glomerulonephritis
was IgA nephropathy at 32.7% of cases, followed by lupus
nephritis (29.8%) and pauci-immune glomerulonephritis
(11.9%). Overall, the mean incidence of glomerulonephri-
tis was 1.3/100,000/year. Between 2007 and 2016, the in-
cidence of all glomerulonephritis taken together remained
stable. The same was true for the incidence of IgA
nephropathy, lupus nephritis and pauci-immune glomeru-
lonephritis. In contrast, we observed a trend towards high-
er creatinine levels, proteinuria and degree of interstitial fi-
brosis at diagnosis.
CONCLUSION: The incidence of glomerulonephritis in the
western part of Switzerland was low and remained stable
over time, in line with European data.
Keywords: glomerulonephritis, renal biopsy, epidemiolo-
gy, Switzerland
Introduction
Glomerulonephritis is a group of kidney diseases charac-
terised by inflammation of the glomeruli, the filtering units
of the kidneys. These inflamed glomeruli can lead to the
pathological leak of protein and blood into the urine. Left
untreated, this chronic inflammation can lead to scarring
and loss of kidney function. Glomerular disease is classi-
fied according to histopathological features on renal biopsy
as well as some immunological characteristics. Glomeru-
lonephritis can be either primary or secondary to a sys-
temic disease. The clinical presentation is variable, ranging
from asymptomatic microhaematuria with or without pro-
teinuria to rapidly progressive renal failure. The sympto-
matology is typically described as nephrotic syndrome or
nephritic syndrome, the former comprising oedema, hy-
poalbuminaemia, proteinuria and dyslipidaemia and the
latter hypertension, renal dysfunction and glomerular
haematuria [1].
Glomerulonephritis is rare, with an estimated worldwide
incidence of 0.5–2.5 per 100,000 patients per year depend-
ing on the specific type [2]. In contrast, the risk of progres-
sion to end-stage renal disease (ESRD) is high, explaining
why glomerulonephritis accounts for 14–20% of cases of
ESRD [3, 4]. The risk of progression to ESRD depends on
the disease subtype. For example, an American retrospec-
tive study reported an incidence of ESRD of 8.72 per 100
person-years for focal segmental glomerulosclerosis and
1.67 per 100 person-years for minimal change disease [5].
Besides, incidence and prevalence depend on sex, age and
geographical location [2].
Apart from the risk of progression to ESRD, the treatment
of the different forms of glomerulonephritis is complicated
and associated with additional morbidity and costs. Ex-
pensive immunosuppressive medication is often necessary
and may lead to infectious, malignant or other complica-
tions. Consequently, the burden of glomerulonephritis to
the healthcare system is substantial. For optimal health-
care planning, detailed epidemiological and demographic
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data are therefore essential. Unfortunately, up to now and
to our knowledge, there are no epidemiological data avail-
able for the incidence, prevalence and treatment modalities
of glomerulonephritis in Switzerland. The absence of such
registries limits the understanding of the natural history
of glomerulonephritis. It also hampers the recruitment of
glomerulonephritis patients into clinical trials in Switzer-
land, thus impeding research and evidence-based treatment
recommendations.
The aim of this study was therefore to describe the inci-
dence of glomerulonephritis in the western part of Switzer-
land compared with international data, as well as the evo-
lution of the incidence over time.
Materials and methods
This retrospective study was approved by the local ethics
committee (CER-VD) and in agreement with the declara-
tion of Helsinki. The study (category A according to the
Swiss human research act) was exempted from informed
consent.
The pathology department of the University Hospital of
Lausanne (CHUV), Switzerland, not only analyses locally
obtained biopsies, but is also the reference centre for the
regional hospitals and peripheral nephrologists from the
cantons Vaud, Fribourg, Valais and Neuchâtel. Data on all
biopsies are stored in a database with information on the
primary diagnosis, biopsy date and the referring nephrolo-
gist. Nephrologists who are not affiliated to a hospital also
refer the patients from their practices with an indication for
renal biopsy to our university centre or one of the region-
al hospitals in order for the renal biopsies to take place. As
such, the biopsies of all patients with a presumed new diag-
nosis of glomerulonephritis in these cantons are analysed
by the pathology department of the CHUV. Therefore, this
dataset is a reliable source for assessment of the incidence
and prevalence of glomerulonephritis in the four cantons.
All biopsies were analysed by the same experienced renal
pathologist (SR).
A first screening included all kidney biopsies analysed and
stored in the database at the CHUV between the 1 Janu-
ary 2007 and the 31 December 2016. In a second step, da-
ta for 2012 were excluded, as for several months all biop-
sies had to be sent to other academic centres for analysis
because of the temporary absence of our renal pathologist
(SR). Transplant biopsies were also excluded.
Thereafter, all written biopsy reports were collected. In or-
der to assess the yearly incidence, only biopsies with a
first diagnosis of primary glomerulonephritis in patients
aged at least 18 years at the time of biopsy were included
in our final analysis. Second or third consecutive biopsies
and biopsies from transplanted or post-mortem kidneys
were excluded, as well as those with an uncertain diagno-
sis. The type of glomerulonephritis was classified as min-
imal change glomerulonephritis, focal segmental glomeru-
losclerosis, IgA nephropathy, membranous
glomerulonephritis, membranoproliferative glomeru-
lonephritis, pauci-immune glomerulonephritis, anti-
glomerular basement membrane glomerulonephritis, lupus
nephritis or fibrillary glomerulonephritis. The classifica-
tion of the different types of primary glomerulonephritis
was based on currently used diagnostic criteria [6–15].
Data on the number of inhabitants in the different cantons
were retrieved from the Federal Office of Statistics. For
each year, the incidence was calculated as the number of
patients newly diagnosed with glomerulonephritis divided
by the number of inhabitants of all the above-mentioned
cantons.
Baseline characteristics such as age, sex and biological re-
sults including serum creatinine and the level of protein-
uria were retrieved from the electronic database of our hos-
pital. The degree of proteinuria was expressed as urinary
protein concentration and protein/creatinine ratio. We al-
so documented details of the biopsy procedure, such as
the needle size used and the number and size of each
sample for each participant. Histological variables includ-
ed the number of glomeruli per sample, the percentage of
glomerular sclerosis and the percentage of interstitial fibro-
sis, as noted by the pathologist in his final report.
As mentioned above, the main objective of this study was
to determine the incidence of glomerulonephritis in the
western part of Switzerland. Secondary outcomes were the
changes in baseline characteristics over time of the patients
with glomerulonephritis and the degree of glomeruloscle-
rosis and interstitial fibrosis, as a proxy of the advancement
of the disease at the time of the biopsy, and thus the rapid-
ity of medical diagnosis.
Statistical methods
Baseline characteristics were expressed as mean ± standard
deviation, median (interquartile range) or percentage, as
appropriate. We used Student’s t-test, Wilcoxon test or chi-
square tests to compare participants’ results and groups.
We used Cuzick’s nonparametric test for trends (nptrend)
and linear regression to examine the evolution of biopsy
rates and the incidence of glomerulonephritis over time. A
p-value below 0.05 was considered significant. All statisti-
cal analyses were performed using STATA 14.2 (StataCorp
LLC, College Station, Texas, USA).
Results
We retrospectively collected all kidney biopsy reports be-
tween 2007 and 2016 (n = 867), from which we removed
transplant biopsies and all biopsies performed in 2012.
Thereafter, we excluded 386 biopsies with other aetiolo-
gies such as diabetic nephropathy, vascular/ischaemic
nephropathy or congenital disorders, biopsies with no di-
agnosis or an uncertain diagnosis, and biopsies in patients
with glomerulonephritis performed for the second, third or
fourth time. The selection process is detailed in figure 1.
A total of 168 met the inclusion criteria, with a mean of
18.7 biopsies per year for nine consecutive years. During
this time period, 52.4% of biopsied patients were men. The
mean age was 50 years.
The mean overall incidence, for all forms of glomeru-
lonephritis combined over the whole 9-year period, was
1.3/100,000/year. The incidence remained stable over time,
as illustrated in figure 2. The most common primary
glomerulonephritis was IgA nephropathy with 32.7% of
cases, followed by lupus nephritis (29.8%) and pauci-im-
mune glomerulonephritis (11.9%). The number of patients
and the year-by-year incidence for each subtype of
glomerulonephritis is shown in table 1. The linear regres-
sion analysis of the incidence of each subtype of glomeru-
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lonephritis showed that the yearly incidence of none of
these subtypes changed over time.
The number of biopsies performed each year per million
inhabitants increased between 2007 and 2016, as shown in
table 2. The analysis of the annual rate of all biopsies in na-
tive kidneys, including biopsies with diagnoses other than
glomerulonephritis and repeat biopsies in the same patient,
but excluding transplant biopsies, revealed a significant in-
crease (p = 0.007).
Clinical characteristics of patients with a first diagnosis of
glomerulonephritis were compared year by year between
2007 and 2016, as detailed in table 3. There was no sig-
nificant change in the gender distribution and age of the
patients. However, creatinine values and proteinuria at the
time of the biopsy did increase significantly over the years.
Regarding histological characteristics, there was a slight
increase in fibrosis and no change in glomerulosclerosis.
With respect to the quality of the biopsies, there was a
slight decrease in the number of glomeruli per sample,
ranging from 37 to 19, although there were still sufficient
to ensure interpretation.
Figure 1: Flow-diagram of biopsy selection.
Figure 2: Evolution of the local incidence of glomerulonephritis over time: all causes combined as well as the most frequent forms of primary
glomerulonephritis. FSGS = focal segmental glomerulosclerosis; GN = glomerulonephritis; IgAN = IgA nephropathy
Original article Swiss Med Wkly. 2020;150:w20353
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 7
Discussion
Taken together, our study shows that the global incidence
of glomerulonephritis in the western part of Switzerland is
approximately 1.3/100,000/year; this incidence remained
stable between 2007 and 2016. IgA nephropathy had the
highest incidence, with 0.40 new cases/100,000 person/
years (32.7% of all cases), followed by lupus nephritis and
pauci-immune glomerulonephritis. Of interest, parameters
of disease progression increased between the beginning
and the end of the study, suggesting that glomerulonephri-
tis was diagnosed at a higher age and more advanced stages
in recent times.
The annual biopsy rate in native kidneys increased (np
trend p = 0.023), suggesting either a more aggressive biop-
sy policy, or an increase of kidney disease burden. Our data
do not allow us to differentiate between these two possi-
bilities. If the biopsy rate were higher due to a more ag-
gressive biopsy policy, this would further support our con-
clusion that the incidence of glomerulonephritis (including
IgA nephropathy) has not increased and was rather stable
in Switzerland over the last decade.
Regarding the stable incidence of glomerulonephritis over
time in our study, international studies describe various
trends, depending on the country and the underlying type
of glomerulonephritis.
For example, a study conducted between 1976 and 2005
in Northern Ireland found an increase in the biopsy rate
from 2.02 to 7.08 per hundred thousand population per
year. IgA nephropathy was the most common diagnosis
(38.8%). The authors showed a significant increase in the
proportion of IgA nephropathy and decrease in membra-
nous nephropathy over time [16].
On the other hand, an Italian study reported an increase in
all subtypes, but also showed that the increase was in fact
only reflecting the better recognition of glomerulonephritis
[17].The global increase shown in some studies can indeed
Table 1: Absolute number of patients and incidence of the different forms of primary glomerulonephritis between 2007 and 2016.
2007 2008 2009 2010 2011 2013 2014 2015 2016 Entire period
n* I† n* I† n* I† n* I† n* I† n* I† n* I† n* I† n* I† n* I†
MCD 0 0 0 0 1 0.07 0 0 0 0 0 0 0 0 1 0.06 1 0.06 3 0.02
FSGS 6 0.42 1 0.07 1 0.06 1 0.06 1 0.06 0 0 0 0 2 0.12 0 0 12 0.09
IgAN 4 0.28 9 0.63 6 0.41 4 0.27 5 0.33 7 0.45 10 0.63 3 0.18 7 0.43 55 0.41
MG 0 0 1 0.07 2 0.13 1 0.06 3 0.2 0 0 1 0.06 1 0.06 1 0.06 10 0.07
Pauci-immune
GN
4 0.28 1 0.07 1 0.06 2 0.13 5 0.33 3 0.19 0 0 1 0.06 3 0.18 20 0.15
Lupus nephritis 5 0.35 6 0.42 7 0.48 5 0.33 10 0.66 6 0.38 3 0.19 5 0.31 3 0.18 50 0.37
Anti-GBM GN 0 0 0 0 0 0 0 0 0 0 1 0.06 0 0 2 0.12 2 0.12 5 0.04
MPG 1 0.07 0 0 0 0 3 0.2 0 0 2 0.12 2 0.12 2 0.12 2 0.12 12 0.09
ITG 1 0.07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0.007
All GN 21 1.5 18 1.26 18 1.24 16 1.09 24 1.6 19 1.23 16 1.21 17 1.07 19 1.18 168 1.3
Population
(million)
1.4 1.427 1.45 1.471 1.496 1.544 1.567 1.588 1.607 13.55
Anti-GBM GN = anti-glomerular basement membrane glomerulonephritis; FSGS = focal segmental glomerulosclerosis; IgAN = IgA nephropathy; ITG = immunotactoid glomeru-
lopathy; MCD = minimal change disease; MG = membranous glomerulonephritis; MPG = membranoproliferative glomerulonephritis Population: in the cantons of Vaud, Fribourg,
Neuchâtel and Valais * Absolute number; † Incidence/100,000 persons/year
Table 2: Annual kidney biopsy rate between 2007 and 2016 per million inhabitants. There was a significant increase (p = 0.007) in the total number of kidney biopsies performed
in the western region of Switzerland (all diagnoses confounded, and excluding transplant biopsies).
Year Number of biopsies Inhabitants (million) Annual biopsy rate (per million)
2007 61 1.400 43.6
2008 62 1.427 43.4
2009 54 1.450 37.2
2010 44 1.470 29.9
2011 60 1.496 40.1
2013 71 1.544 46.0
2014 84 1.567 53.6
2015 88 1.588 55.4
2016 103 1.607 64.1
Table 3: Comparison of baseline characteristics of patients with firstly diagnosed primary glomerulonephritis between 2007 and 2016.
2007 2008 2009 2010 2011 2013 2014 2015 2016 p-val-
ue
Women (%) 38 39 50 56.3 54.2 57.9 50 64.7 21.1 0.63
Age 45 ± 17 48.4 ± 20 47.9 ± 18 49.8 ± 18 50 ± 13 49.2 ± 19 58.8 ± 15 54.7 ± 20 56.8 ± 18 0.06
Creatininaemia (µmol/l) 166 (86–188) 156
(91–190)
92 (65–228) 92 (65 –228) 110 (68–200) 130 (89–169) 245
(119–400)
107 (70–180) 160
(128–250)
0.16
Proteinuria/creatininuria ratio
(g/mol)
233
(127–335)
244
(58–447)
188
(96–252)
190(48–660) 412
(199–596)
172
(123–363)
606
(484–912)
294
(176–633)
236
(124–729
0.4
Glomerulosclerosis (%) 16.6 22.6 16.6 25.7 22.6 27.1 21.9 16.8 21.2 0.21
Interstitial fibrosis (%) 21.9 27.7 14.3 20.7 23.7 28.1 34.8 19.3 28.4 0.22
Data are expressed as mean ± standard deviation, median (interquartile range) or percentage, as appropriate.
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be influenced by an increase in the number of biopsies per-
formed [18]. The indication for renal biopsy has widened
over time, due in part to the increased safety of the pro-
cedure. Another Italian study demonstrated how the biop-
sy policies evolved, with a significant increase of biopsies
performed for the indication of isolated urinary abnormal-
ities [19]. In our population, we also found a significant
increase in the number of biopsies carried out per mil-
lion inhabitants over the study period, consistent with these
assumptions. However, the change in biopsy policy was
probably less important in Switzerland, owing to the al-
ready highly developed healthcare system. Moreover, our
data are recent, whereas other studies analysed older da-
ta at a time where access to biopsy was probably lower.
This could explain why the slight increase in the number
of biopsies over time was not accompanied by an increase
in the incidence.
Regarding the subtypes of glomerulonephritis, IgA
nephropathy was the most frequently diagnosed subtype,
with a stable incidence of 0.40/100,000/year. This is lower
compared with international results. In Europe, the inci-
dence of IgA nephropathy varies between 0.8 and 3.1 cas-
es/100,000/year, with the lowest reported incidence in Italy
and the highest in France [18]. In other registries, the re-
ported incidence was 1.47/year/100,000 in North-western
Italy [19], and 4.8 in Finland [18]. In Asia, IgA nephropa-
thy has generally a higher incidence than in Europe, which
is not explained just by race differences. For example, an
incidence of 4.5/100,000 has been reported in Japan [20]
versus 10.5/100,000 in Australia [21].
Despite its high incidence, IgA nephropathy is not the most
frequent type of glomerulonephritis in developing coun-
tries. For example, a single-centre study from India re-
ported that IgA nephropathy accounted for 10.25% of all
cases of glomerulonephritis, whereas the most frequent
type was minimal change glomerulonephritis (25.42%),
followed by focal segmental glomerulosclerosis (22.58%)
[22]. The same trend was seen in Africa, with minimal
change disease again the most frequent glomerulonephritis
(16.5% of all cases), followed by focal segmental glomeru-
losclerosis (15.9%) and IgA nephropathy (2.8%) [23]. In
South America, a Brazilian study found focal segmental
glomerulosclerosis to be the most frequent aetiology
(28.8%) and only 18.3% were IgA nephropathy [24]. Fi-
nally, epidemiological studies in the Middle East reported
that focal segmental glomerulosclerosis was the most com-
monly diagnosed glomerulonephritis (35% of cases) in
Iraq, whereas IgA nephropathy accounted for only 7% of
cases [25] and in Saudi Arabia focal segmental glomeru-
losclerosis accounted for 39.8% of cases [26].
It remains an open question why the incidence of IgA
nephropathy was lower in Switzerland than in surrounding
countries. It could be that screening and biopsy policies
differ between Switzerland and other European countries,
such as considering biopsy for asymptomatic urinary ab-
normalities. Wirta et al. demonstrated the importance of
biopsy policy in a Finnish study; they compared data from
a university hospital with data from surrounding central
hospitals. The increased biopsy rate in the university hos-
pital was linked to a significant increase in the reported
glomerulonephritis incidence, despite a similar population
[18]. Another possible explanation may be that our data-
base is not complete. In this context, one could argue that
some patients living in the canton of Vaud were taken care
of by another academic hospital in a different canton, such
as Geneva or Bern. This occurs in general only if there is
a special medical indication, which is unlikely considering
the similar levels of medical competence of the different
university centres.
For lupus nephritis, we noted a mean incidence of 0.37/
100,000/year (29.8% of all glomerulonephritis cases) in
our study, with a trend towards a decrease of its incidence
in recent years.
Interestingly, we observed a trend towards an increase in
the mean age of patients at the time of the biopsy, although
this did not reach statistical significance, probably due to
the relatively small sample size. Patients with glomeru-
lonephritis diagnosed in 2007 were almost ten years
younger than patients newly diagnosed in 2016. This trend
is also seen internationally [16, 17, 19, 27]. Whether this is
a simple consequence of the worldwide ageing population
or linked to the increased safety and availability of renal
biopsies leading to a more expanded use in older patients
remains an open question. The relatively high degree of
glomerulosclerosis and interstitial fibrosis reminds us that
glomerulonephritis can be extremely aggressive and is of-
ten advanced at the time of diagnosis, underlining the need
for rapid diagnostic strategies.
Notably, the proportion of ESRD due to glomerulonephri-
tis is possibly changing. As stated above, glomerulonephri-
tis used to account for up to 20% of cases of ESRD [2].
In the United States renal data system, this percentage is
slowly decreasing, with a prevalence of 18% in 1999, 16%
in 2006 and 15% in 2016 [28]. This could be explained
by improvements in treatment and also the relative in-
crease of diabetes nephropathy, which is actually the lead-
ing cause of ESRD and has seen its incidence steadily in-
crease worldwide over the last decades. In Switzerland,
data on patients with ESRD have been systematically
recorded only since 2013 in the Swiss national dialysis
registry (srrqap, Swiss renal registry and quality assess-
ment programme). According to this registry, there was no
increase in the proportion of glomerulonephritis amongst
dialysis patients in Switzerland between 2015 and 2018
(see table 4A). The proportion of incident ESRD patients
with biopsy-proven glomerulonephritis also did not change
(table 4B). Clearly, this period of 4 years is too short
to draw definite conclusions on trends. Interestingly, in
line with the low incidence of patients with newly diag-
nosed glomerulonephritis in the French-speaking cantons
outlined above, the prevalence and incidence of patients
with ESRD due to glomerulonephritis is also slightly low-
er than in other countries.
Our results should be interpreted in the light of the
strengths and limitations of the study. Firstly, the presented
results are based on a small number of cases, analysed over
a relatively short period of time. As mentioned, we based
our analyses on the population of the cantons that send
their biopsies to the pathology department of our univer-
sity hospital. It is nevertheless possible that some biopsies
were sent elsewhere, or that some patients chose to go to
a different hospital outside of their home canton. Besides,
we excluded about 13% of the biopsy reports because of
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uncertainty in the diagnosis. This may have slightly low-
ered the incidence rates.
Despite these limitations, our study provides for the first
time data on the regional epidemiology of glomeru-
lonephritis in the French-speaking part of Switzerland. In
the future, the analysis could be expanded to all the other
tertiary referring centres in Switzerland, in order to in-
crease the number of cases and obtain results representing
the whole country.
Overall, our data shows that the incidence of glomeru-
lonephritis in the western part of Switzerland is lower than
in surrounding countries, and rather stable over the last
decade. The most frequent glomerulonephritis was IgA
nephropathy, consistent with international data from devel-
oped countries.
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